Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

Rituximab 169 Cyclophosphamide 158 fludarabine 76 Lenalidomide 73 Vincristine 70 fludarabine phosphate 63 Etoposide 59 Doxorubicin 56 Prednisone 54 venetoclax 49 Cytarabine 48 Dexamethasone 43 Filgrastim 39 Peripheral Blood Stem Cell Transplantation 38 Methotrexate 38 Bendamustine Hydrochloride 38 ibrutinib 37 obinutuzumab 36 Gemcitabine 31 pembrolizumab 27 Melphalan 27 Bortezomib 27 Alemtuzumab 25 Radiotherapy 23 Nivolumab 21 Carboplatin 21 Tacrolimus 20 Granulocyte Colony-Stimulating Factor 20 Busulfan 20 Whole-Body Irradiation 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ice × Lymphoid × Clear all

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡